Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Promising data for Citius combo cream
March 2016
EDIT CONNECT

SHARING OPTIONS:

MAYNARD, Mass.—Top-line data was announced recently from Citius Pharmaceuticals Inc.’s first Phase 2a clinical trial of hydrocortisone acetate (HC) and lidocaine hydrochloride (L) as single agents and in combination (HC+L) in patients with grade I and II hemorrhoids. Patients were treated twice daily for two weeks with either placebo or one of the six active drug treatments (i.e., two concentrations of each HC, L and HC +L). Within the first few days of treatment, the highest concentration of the HC+L product was directionally superior to the placebo as measured by the number of subjects experiencing a minimum of two levels improvement from baseline according to the Global Score of Disease Severity scale. Though the study wasn’t powered for statistical significance, the data also suggest the combination may perform better than HC or L alone.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.